Spain’s Grifols has agreed to buy U.S.-based Talecris Biotherapeutics, which makes plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products – Reuters
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply